Vistagen Therapeutics, Inc.

Vistagen is a late clinical-stage biotechnology company engaged in the research, development, and potential commercialization of novel treatments for central nervous system and women's health conditions. The company's pipeline centers on intranasal pherine product candidates designed with a non-systemic neurocircuitry-focused mechanism of action. Its drug candidates include fasedienol for social anxiety disorder, itruvone for major depressive disorder, refisolone for menopausal vasomotor symptoms and premenstrual dysphoric disorder, PH15 for cognitive and psychomotor impairment caused by mental fatigue, and PH284 for cancer cachexia. The company also investigates AV-101, an oral prodrug targeting neurological conditions. Its target population comprises patients experiencing these severe conditions, including individuals suffering from social phobias, depression, and menopausal hot flashes.

The company conducts clinical development programs primarily within the United States and has performed exploratory clinical studies in Mexico. It also maintains intellectual property portfolios across domestic and foreign markets, holding granted patents and pending applications in the United States and international jurisdictions such as Europe and Japan.

Summary of the business section of Vistagen Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of March 31, 2026, we employed 41 full-time employees; 30 full-time employees work in research and development and laboratory support services, and 11 full-time employees work in management, corporate development and communications, legal, human resources, and other general and administrative roles.”